First European patients treated with BTG ’ s drug-eluting bead
BTG (LON:BTG) said today that the 1st batch of patients in the European Union were treated with its DC Bead Lumi radiopaque drug-eluting bead. Two patients were treated for hepatocellular carcinoma and 1 patient was treated for malignant colorectal cancer metastasized to the liver. The bead, which is the 1st commercially available radiopaque drug-eluting bead in the EU, uses doxorubicin or irinotecan to locally treat tumors. Get the full story at our sister site, Drug Delivery Business News. The post First European patients treated with BTG’s drug-eluting bead appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - April 20, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Oncology Pharmaceuticals Wall Street Beat BTG Source Type: news

Liver progenitor cells are involved in the development of hepatic tumors
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) The malignant transformation of hepatocytes is the origin of most hepatocellular carcinomas, an aggressive type of liver cancer with high mortality rates. But these cells do not act alone. Research conducted by scientists at the Spanish National Cancer Research Centre (CNIO) reveals how hepatocytes 'recruit' and 'instruct' liver progenitor cells to contribute to the hepatic lesions. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 18, 2017 Category: Cancer & Oncology Source Type: news

Hep C Treatment Triumph Drives Broader Focus for ILC 2017 Hep C Treatment Triumph Drives Broader Focus for ILC 2017
Clinical trial results for biliary cirrhosis and hepatocellular carcinoma are highly anticipated at the upcoming International Liver Congress (ILC).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 11, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Metabolic mechanism identified for R-LA induced cell death in liver cancer cells
(Mary Ann Liebert, Inc./Genetic Engineering News) A new study that measured metabolite levels over time in starved rat liver cancer cells showed that treatment with a form of alpha-lipoic acid (LA) inhibited glucose uptake and glycolysis, and led to decreased cellular glucose production from non-carbohydrate sources, which may help explain how the naturally occurring R enantiomeric form of LA (R-LA) promotes the death of hepatoma cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 11, 2017 Category: Global & Universal Source Type: news

The IT-LIVER European consortium unveils new TGF-beta functions in liver cancer
(IDIBELL-Bellvitge Biomedical Research Institute) Recent research results from the European consortium IT-Liver provide a better understanding of the role of the TGF-beta cytokine in liver cancer. Their work, published in Cancer Letters, shows how the TGF-beta cytokine is able to modulate not only the migratory capacity of the hepatocellular carcinoma cell but also its capacity as a tumor initiator cell. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 29, 2017 Category: Global & Universal Source Type: news

A novel molecular link between cholesterol, inflammation and liver cancer
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) Hepatocellular carcinoma (HCC) is a deadly disease with no effective cure that develops in the context of liver diseases associated with chronic inflammation. New paper describes how important is the protein c-Fos for HCC development, because it affects cholesterol homeostasis in hepatocytes. Using genetically modified mouse models, researchers at the Spanish National Cancer Research Centre (CNIO) experimentally document how c-Fos modulates premalignant hepatocyte transformation and how this is linked to cholesterol and inflammation. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 29, 2017 Category: Global & Universal Source Type: news

Overweight young men 'more likely to get severe liver disease'
Conclusion This cohort study aimed to assess whether a high BMI in late adolescence is associated with an increased risk of severe liver disease and liver cancer in later life. The researchers generally found a higher BMI was associated with an increased risk of severe liver disease, including liver cancer. A diagnosis of type 2 diabetes during follow-up was associated with a further increased risk of severe liver disease, regardless of BMI at the start of the study. This study included a very large population, and has used reliable sources of data for medical diagnoses and cause of death. But there are limitations to ...
Source: NHS News Feed - March 21, 2017 Category: Consumer Health News Tags: Obesity Cancer Source Type: news

Necrosis of HCC After Preoperative Portal Vein Embolization Necrosis of HCC After Preoperative Portal Vein Embolization
Might portal vein embolization prior to liver resection have an anti-tumor effect on hepatocellular carcinoma?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 10, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Grant awarded to Sanford Simon will fund research to treat rare liver cancer
(Rockefeller University) Dr. Sanford Simon, head of the Laboratory of Cellular Biophysics at Rockefeller University, has been awarded a $600,000 grant by the Fibrolamellar Cancer Foundation to develop a therapy for fibrolamellar hepatocellular carcinoma. This disease typically occurs in adolescents and young adults who have no history of liver disease, and there is no standard regimen for this often lethal form of cancer. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 8, 2017 Category: Biology Source Type: news

BTG wins CE Mark for DC Bead Lumi radiopaque drug-eluting bead
BTG (LON:BTG) said today that it won CE Mark clearance in the European Union for its DC Bead Lumi radiopaque drug-eluting bead. The bead is designed to be loaded with doxorubicin or irinotecan to locally treat tumors in patients with hepatocellular carcinoma and malignant colorectal cancer metastasised to the liver. The company’s DC Bead Lumi also features real-time visible confirmation of the bead’s location, which the company claims will enhance control in transarterial chemoembolisation procedures. Get the full story at our sister site, Drug Delivery Business News. The post BTG wins CE Mark for DC ...
Source: Mass Device - March 7, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Oncology Pharmaceuticals Regulatory/Clearance Wall Street Beat BTG Source Type: news

Immunotherapies, Novel Agents in Hepatocellular Carcinoma
This video examines the promise of recent trials studying single-agent immunotherapy as well as ongoing trials testing combinations of immune-checkpoint inhibition. (Source: CancerNetwork)
Source: CancerNetwork - March 6, 2017 Category: Cancer & Oncology Authors: Ghassan K. Abou-Alfa, MD Tags: Videos Gastrointestinal Cancers Source Type: news

Liver tumor growth in mice slowed with new chemo-immunotherapy treatment
Hepatocellular carcinoma is the most common form of liver cancer, but treatment options are limited and many patients are diagnosed in late stages when the disease can't be treated. Now, researchers have developed a new treatment that combines chemotherapy and immunotherapy to significantly slow tumor growth in mice. The researchers believe that with more research, the strategy could be translated to benefit patients with the disease. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 28, 2017 Category: Science Source Type: news

Liver tumor growth in mice slowed with new chemo-immunotherapy treatment
(University of Missouri-Columbia) Hepatocellular carcinoma is the most common form of liver cancer, but treatment options are limited and many patients are diagnosed in late stages when the disease can't be treated. Now, University of Missouri School of Medicine researchers have developed a new treatment that combines chemotherapy and immunotherapy to significantly slow tumor growth in mice. The researchers believe that with more research, the strategy could be translated to benefit patients with the disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 28, 2017 Category: Global & Universal Source Type: news

Genetic Variant Linked to Liver Cancer Risk After HCV Eradication Genetic Variant Linked to Liver Cancer Risk After HCV Eradication
A single nucleotide polymorphism (SNP) in the tolloid-like 1 (TLL1) gene is associated with the development of hepatocellular carcinoma (HCC) after eradication of hepatitis C virus (HCV) infection, researchers from Japan report. (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 22, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

High Rates of Hepatocellular Carcinoma After Hepatitis C Treatment High Rates of Hepatocellular Carcinoma After Hepatitis C Treatment
Patients treated with direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV)-related cirrhosis appear to have high rates of hepatocellular carcinoma (HCC). (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 8, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Gold standard monitoring of HCC in patients with cirrhosis is cost-effective
(Wiley) Hepatocellular carcinoma (HCC) is the leading cause of death in patients with cirrhosis. A new analysis indicates that following screening guidelines for HCC in cirrhotic patients is lifesaving and cost-effective compared with 'real life' monitoring. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 8, 2017 Category: Global & Universal Source Type: news

Regorafenib granted priority review in the U.S. for second-line treatment of liver cancer
Bayer announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to the supplemental New Drug Application (sNDA) for regorafenib for the second-line treatment of patients with unresectable hepatocellular carcinoma (uHCC) in the U.S. (Source: World Pharma News)
Source: World Pharma News - February 7, 2017 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

Risk of liver cancer is low in patients with cirrhosis
(Wiley) Although one of the most serious complications of cirrhosis is liver cancer, or hepatocellular carcinoma (HCC), an analysis of health records revealed that the 10-year incidence of HCC in UK patients with cirrhosis is 4 percent or lower. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 1, 2017 Category: Cancer & Oncology Source Type: news

Onxeo closes enrolment in Phase III trial of Livatag to treat hepatocellular carcinoma
French-based biopharmaceutical firm Onxeo has closed enrolment for its Phase III clinical trial (ReLive) of Livatag for the treatment of advanced hepatocellular carcinoma (HCC), a primary liver cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - January 25, 2017 Category: Pharmaceuticals Source Type: news

SBRT Equivalent to TACE as Bridge to Transplant for Patients With HCC
Use of stereotactic body radiation therapy (SBRT) was equally effective as transarterial chemoembolization (TACE) as a method of bridge to transplant among patients with hepatocellular carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - January 23, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO 2017 Gastrointestinal Cancers Symposium Liver, Gallbladder, and Biliary Tract Cancers News Source Type: news

Second-Line Regorafenib Extends Survival in Sorafenib-Tolerant HCC Patients
This video examines an exploratory analysis of the RESORCE trial, which tested regorafenib vs placebo in hepatocellular carcinoma patients following radiographic progression on sorafenib. (Source: CancerNetwork)
Source: CancerNetwork - January 21, 2017 Category: Cancer & Oncology Authors: Richard S. Finn, MD Tags: Conferences/ASCO 2017 Gastrointestinal Cancers Symposium Videos Gastrointestinal Cancers Source Type: news

Mount Sinai researchers involved in successful phase 3 trial of drug for liver cancer
(The Mount Sinai Hospital / Mount Sinai School of Medicine) An international phase 3 trial has found that the drug regorafenib improved survival in patients with advanced hepatocellular carcinoma, a form of liver cancer, giving people who previously had no other options a better chance at survival. Results from the study, which included researchers at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, were recently published in The Lancet. The trial, funded by Bayer, included 152 sites in 21 countries. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 18, 2017 Category: Cancer & Oncology Source Type: news

Liver Cirrhosis Tied to Hepatocellular Cancer Recurrence Liver Cirrhosis Tied to Hepatocellular Cancer Recurrence
Compared with patients with a normal liver who undergo curative hepatectomy because of de novo hepatocellular carcinoma (HCC), those with liver cirrhosis may have a higher hepatocarcinogenic potential, researchers say.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 13, 2017 Category: Surgery Tags: Gastroenterology News Source Type: news

What Precautions Should A Childcare Center Take For A Child with Hepatitis C Infection?
Discussion It is estimated that 180 million people worldwide are infected with Hepatitis C (HCV) which includes ~11 million children. In the United States it is estimated that there were 30,500 acute HCV cases in 2014, and 2.7-3.9 million people with chronic HCV. Many infections are not identified. It is estimated that “…only 5-15% of HCV-infected children in the United States are identified.” Problems associated with HCV include acute hepatitis (including fever, malaise, dark-urine, abdominal pain, jaundice, appetite loss, nausea, emesis, clay-colored stools), acute fulminant hepatitis (not common in c...
Source: PediatricEducation.org - January 9, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Real-Life Experience With Sorafenib for HCC in HIV Patients Real-Life Experience With Sorafenib for HCC in HIV Patients
A new study provides insight into the real-life efficacy of sorafenib among HIV-infected patients with hepatocellular carcinoma.AIDS (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 6, 2017 Category: Infectious Diseases Tags: Hematology-Oncology Journal Article Source Type: news

One more piece in the puzzle of liver cancer identified
Scientists are one step closer to unraveling the mechanisms behind liver cancer. The researchers discovered that RAF1, a protein known as an oncogene in other systems, unexpectedly acts as a tumour suppressor in hepatocellular carcinoma. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 21, 2016 Category: Science Source Type: news

One more piece in the puzzle of liver cancer identified
(University of Vienna) Manuela Baccarini and her team at the Max F. Perutz Laboratories (MFPL) of the University of Vienna and Medical University of Vienna are one step closer to unraveling the mechanisms behind liver cancer. The researchers discovered that RAF1, a protein known as an oncogene in other systems, unexpectedly acts as a tumor suppressor in hepatocellular carcinoma. The study is published in the renowned journal Nature Communications. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 21, 2016 Category: Cancer & Oncology Source Type: news

Four-Year Entecavir Therapy in Chronic Hepatitis B Patients Four-Year Entecavir Therapy in Chronic Hepatitis B Patients
This study assessed outcomes of long-term entecavir therapy in patients with chronic hepatitis B. Does it reduce development of hepatocellular carcinoma and cirrhotic complications?Liver International (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - December 6, 2016 Category: Transplant Surgery Tags: Infectious Diseases Journal Article Source Type: news

Living With Cancer: Hepatocellular carcinoma
Hepatocellular carcinoma Hepatocellular carcinoma is the most common type of primary liver cancer. Hepatocellular carcinoma occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection. Fight the flu bug by keeping hands clean During and after cancer treatment, it's common to feel vulnerable to colds [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 2, 2016 Category: Databases & Libraries Source Type: news

Jet lag and obesity share similar pathways to liver cancer
Since 1980, the incidence of hepatocellular carcinoma, the most common type of liver cancer, has nearly tripled, and obesity related liver disease is one of the driving forces behind the increasing number of cases. Researchers are now examining how other lifestyle factors may affect your health. Using mice, the scientists show that repeated jet lag increases both obesity related liver disease and the risk of liver cancer. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 23, 2016 Category: Science Source Type: news

Jet lag and obesity share similar pathways to liver cancer
(Cell Press) Since 1980, the incidence of hepatocellular carcinoma, the most common type of liver cancer, has nearly tripled, and obesity related liver disease is one of the driving forces behind the increasing number of cases. Researchers are now examininng how other lifestyle factors may affect your health. Using mice, the scientists show that repeated jet lag increases both obesity related liver disease and the risk of liver cancer. The study appears in Cancer Cell. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 23, 2016 Category: Cancer & Oncology Source Type: news

New Score Helps Predict HCC Recurrence After Liver Transplant New Score Helps Predict HCC Recurrence After Liver Transplant
A new scoring system based on tumor characteristics can help predict the risk of recurrence of hepatocellular carcinoma (HCC) after liver transplantation, new research shows.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - November 23, 2016 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Fatty Liver Disease in Teens Parallels Obesity Rise Fatty Liver Disease in Teens Parallels Obesity Rise
The increase in liver disease in adolescents in the United States, which is related to the obesity epidemic, will have implications into the future, as cases of hepatocellular carcinoma increase.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2016 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

The Surgical Management of Peritoneal Carcinomatosis of Colorectal Origin
In the United States, approximately 20% of patients with colorectal cancer present with distant metastasis at diagnosis. In 25% of cases, the peritoneal cavity is the only site of metastatic disease, which is not indicative of a generalized systemic disease, as is the case with lung or liver metastases. (Source: CancerNetwork)
Source: CancerNetwork - November 15, 2016 Category: Cancer & Oncology Authors: Daniel M. Labow, MD Ramy Fouad, MD Shanel B. Bhagwandin, DO, MPH Tags: Colorectal Cancer Oncology Journal Source Type: news

Direct-Acting Antivirals for Hep C Might Worsen Liver Cancer Direct-Acting Antivirals for Hep C Might Worsen Liver Cancer
For patients with hepatitis C and cirrhosis who develop hepatocellular carcinoma during treatment or follow-up, there is a trend toward disease worsening, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 13, 2016 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Bristol-Myers Squibb to collaborate with Chapel Hill data firm
Chapel Hill-based clinical data company Target PharmaSolutions – which secured funding from Rex Health Ventures earlier this year – has landed two new collaborations with Bristol-Myers Squibb. The collaborations will focus on examining treatment patterns in nonalcoholic steatohepatitis (fatty liver disease) and hepatocellular carcinoma (liver cancer), Targ et PharmaSolutions announced Thursday. The collaborations also provide Target PharmaSolutions “additional strength as we continue to bring… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 11, 2016 Category: Pharmaceuticals Authors: Jennifer Henderson Source Type: news

Regorafenib from Bayer submitted to health authorities seeking approval in second-line treatment of liver cancer
Bayer has announced the submission of applications to extend the marketing authorization for its oral multi-kinase inhibitor regorafenib in the U.S., Japan and Europe, for the second line treatment of patients with unresectable hepatocellular carcinoma (HCC). Regorafenib is already approved under the brand name Stivarga® in many countries to treat metastatic colorectal cancer and metastatic gastrointestinal stromal tumors. (Source: World Pharma News)
Source: World Pharma News - November 9, 2016 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

Regorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer (for specialized target groups only)
Regulatory submissions in the U.S., Japan and Europe were completed based on data from the Phase III RESORCE study, in which regorafenib demonstrated statistically significant improvement in overall survival / Currently there are no approved therapies for the treatment of unresectable hepatocellular carcinoma (HCC) in the second-line setting (Source: Bayer Company News)
Source: Bayer Company News - November 7, 2016 Category: Pharmaceuticals Source Type: news

Successful Liver Transplantation Between HIV-Positive Donor and HIV-Positive Recipient Successful Liver Transplantation Between HIV-Positive Donor and HIV-Positive Recipient
Liver transplantation for hepatocellular carcinoma is feasible where both the donor and recipient are HIV-positive, according to a case report.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - November 4, 2016 Category: Surgery Tags: Transplantation News Source Type: news

MRI With Liver Contrast Edges Ultrasound in Spotting Cancer MRI With Liver Contrast Edges Ultrasound in Spotting Cancer
Magnetic resonance imaging (MRI) with liver-specific contrast can lead to a higher detection rate for hepatocellular carcinoma (HCC) than standard ultrasound screening, according to Korean researchers.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 29, 2016 Category: Radiology Tags: Radiology News Source Type: news

Study: Onconase, Malaria Drug Extends Mesothelioma Survival
A new treatment combining two existing drugs — one derived from frog eggs and another given to combat malaria — may be the key to extending mesothelioma survival. Scientists at Tongji University in Shanghai, China, discovered that mixing Onconase, an enzyme present in early-stage leopard frog embryos, with antimalarial drug dihydroartemisinin (DHA) synergistically suppressed growth and angiogenesis of malignant mesothelioma, an aggressive cancer linked to asbestos exposure. Researchers investigated the antitumor effects of the drug combination in two ways — in vitro (in a test tube) and in vivo (in a li...
Source: Asbestos and Mesothelioma News - September 29, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: antitumor extending mesothelioma survival malaria drug malignant pleural mesothelioma mesothelioma clinical trial mesothelioma treatment onconase onconase clinical trial tongji university Source Type: news

Cannabis And Cancer
With ever-increasing costs of conventional healthcare, and continuing issues with insurance coverage, alternative medicine is growing in popularity. Inasmuch as it is still officially denigrated, cannabis is about as "alternative" as it gets. This, despite no shortage of historic references to cannabis, or its extract marijuana (prepared from the dried and crushed flowers and leaves of the plant) as to its medicinal effects. Chinese Emperors Fu Hsi (2900 BC) and Shen Nung (2700 BC) are said to have touted its healing effects. Some authorities claim that the anointing oil in Exodus 30:22-25 contained cannabis, an...
Source: Science - The Huffington Post - September 23, 2016 Category: Science Source Type: news

Blood Salvage and Autotransfusion During Liver Transplant Blood Salvage and Autotransfusion During Liver Transplant
Could the autotransfusion of salvaged red blood cells during liver transplantation contribute to the recurrence of hepatocullar carcinoma after transplantation?Annals of Surgery (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 22, 2016 Category: Intensive Care Tags: Transplantation Journal Article Source Type: news

Incidence of HCC in Untreated Subjects With Chronic HBV Incidence of HCC in Untreated Subjects With Chronic HBV
What factors influence the incidence of hepatocellular carcinoma in patients with untreated, chronic hepatitis B infection?Liver International (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 15, 2016 Category: Infectious Diseases Tags: Hematology-Oncology Journal Article Source Type: news

HCV Treatment Failure and Risk of Hepatocellular Carcinoma HCV Treatment Failure and Risk of Hepatocellular Carcinoma
Are patients with hepatitis C who receive antiviral treatment but fail to achieve sustained virological response more likely to develop hepatocellular carcinoma than untreated patients?Journal of Viral Hepatitis (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 9, 2016 Category: Radiology Tags: Gastroenterology Journal Article Source Type: news

US firm twoXAR and Stanford University partner to identify drug candidates for HCC
US-based twoXAR has collaborated with Stanford University School of Medicine ’s Asian Liver Centre in a bid to support research for identifying drug candidates targeting hepatocellular carcinoma (HCC). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 8, 2016 Category: Pharmaceuticals Source Type: news

FDA Approves Keytruda (Pembrolizumab) for Head and Neck Cancer
By Stacy SimonThe US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) to treat people with head and neck squamous cell carcinoma that has spread or come back after previous chemotherapy treatment. It’s the first immunotherapy drug approved for head and neck cancer. Keytruda is already approved for melanoma and non-small cell lung cancer.The FDA based its approval on a clinical trial of 174 people with head and neck squamous cell carcinoma that had spread or come back after they were treated with platinum-based chemotherapy. Tumors shrank or disappeared in 16% of the participants who were given...
Source: American Cancer Society :: News and Features - August 9, 2016 Category: Cancer & Oncology Tags: Oral Cavity and Oropharyngeal Cancer Source Type: news

Primary liver carcinoma may be misclassified based solely on major imaging features
(American Roentgen Ray Society) A study released in the July 2016 issue of the American Journal of Roentgenology found that biphenotypic primary liver carcinoma may be misclassified as hepatocellular carcinoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 1, 2016 Category: Global & Universal Source Type: news

HBV X mutation increases hepatocarcinogenesis risk
In patients with chronic hepatitis B virus infection, the presence of the X-gene T1753V mutation in the viral genome is associated with an elevated risk of progression to hepatocellular carcinoma, suggests research. (Source: MedWire News)
Source: MedWire News - July 29, 2016 Category: Consumer Health News Tags: HBV Source Type: news

Sorafenib treatment alters immunosuppressive phenotypes in hepatocellular carcinoma
( JCI Journals ) In this issue of JCI Insight, Yasmin Thanavala and colleagues at Roswell Park Cancer Institute evaluated the immune response in a small cohort of patients with advanced hepatocellular carcinoma before and after treatment with sorafenib. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2016 Category: Cancer & Oncology Source Type: news